| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/31/2003 | US20030143595 Isolated and/or recombinantly produced polypeptide; use in regulating spermatogenesis, cell differentiation and proliferation |
| 07/31/2003 | US20030143589 Drug metabolizing enzymes |
| 07/31/2003 | US20030143588 Phosphodiesterases |
| 07/31/2003 | US20030143579 Inhibitors of apoptosis |
| 07/31/2003 | US20030143546 Breast cancer transcription factor gene and uses |
| 07/31/2003 | US20030143541 Isolated nucleic acid molecule encoding a polypeptide that mediates a detectable physiological or behvioral effect in mammals |
| 07/31/2003 | US20030143292 For reducing pain, inflammation, stiffness, or discomfort in a mammal |
| 07/31/2003 | US20030143285 For therapy andprophylaxis of disease-like conditions caused by extreme body fluid discharge |
| 07/31/2003 | US20030143284 Food product comprising a high level of natural anti-secretory protein |
| 07/31/2003 | US20030143282 Adenosine A3 receptor agonist |
| 07/31/2003 | US20030143281 Composition of restricted cancer cells which produce cancer cell proliferation suppressive materials, and uses thereof |
| 07/31/2003 | US20030143269 Tamper-resistant oral opioid agonist formulations |
| 07/31/2003 | US20030143259 Topical treatment or prevention of ocular infections |
| 07/31/2003 | US20030143250 Pharmaceutical compositions comprising cyclosporins |
| 07/31/2003 | US20030143249 Method of treating pain |
| 07/31/2003 | US20030143247 For therapy of infections with hepatitis or picornaviruses |
| 07/31/2003 | US20030143245 Multivalent streptococcal vaccine compositions and methods for use |
| 07/31/2003 | US20030143243 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 07/31/2003 | US20030143241 For inhibiting hepatitis E virus (HEV) infection |
| 07/31/2003 | US20030143239 Non-anaphylactic forms of grass pollen Phl p 6 allergen and their use |
| 07/31/2003 | US20030143238 Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
| 07/31/2003 | US20030143237 Creating an immune response in the mammal to at least part of the amino acid sequence of an alpha fetoprotein molecule; where immune response comprises activating alpha fetoprotein peptide specific T lymphocytes against cancer cells |
| 07/31/2003 | US20030143236 For irreversibly inhibiting infectivity of a mammalian cell by a human rhinovirus |
| 07/31/2003 | US20030143234 For therapy of microbial organism infection |
| 07/31/2003 | US20030143232 Incubating survivin and p34cdc2-cyclin B1 kinase complex in presence of an agent; determining whether agent modulates phosphorylation of survivin by p34cdc2-cyclin B1 kinase complex, identifying an agent which modulates phosphorylation |
| 07/31/2003 | US20030143229 FAPalpha -specific antibody with improved producibility |
| 07/31/2003 | US20030143228 Human telomerase reverse transcriptase as a class-II restricted tumor-associated antigen |
| 07/31/2003 | US20030143223 Modulating the activity of one or more elements in the complement/lipid pathway |
| 07/31/2003 | US20030143220 Hybrid immunoglobulins |
| 07/31/2003 | US20030143218 As target for drug screening |
| 07/31/2003 | US20030143217 For therapy of smooth muscle cell hyperplasia; cancer therapy |
| 07/31/2003 | US20030143216 For therapy of fungal infections; for detecting chitin, binding chitin |
| 07/31/2003 | US20030143215 Carbonyl stress-ameliorating agents |
| 07/31/2003 | US20030143212 Corneal cells expressing active agents and methods of use thereof |
| 07/31/2003 | US20030143210 Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof |
| 07/31/2003 | US20030143206 Increasing the level of at least one isoform of the enzyme nitric oxide synthase in the cells of the ano-rectal region for therapy of anal disease |
| 07/31/2003 | US20030143204 Making the inhibitor consisting of an RNA function inhibiting sequence that is specific to expressible nucleic acid sequence in mammal; inserting the inhibitor into a vessel in the mammal; delivering function inhibiting sequence to a cell |
| 07/31/2003 | US20030143199 Administering to a mammal subject to interferon treatment a compound which is an antagonist of IL-4 or IL-13 signal transduction pathway in an amount effective to enhance efficacy |
| 07/31/2003 | US20030143198 Method for preparing a physiologically active il-18 polypeptide |
| 07/31/2003 | US20030143197 Administering to the animal omega interferon (IFN) at a dosage and activity for the disease state treated sufficient to induce a therapeutic response in the animal |
| 07/31/2003 | US20030143196 To regulate an immune response in an animal |
| 07/31/2003 | US20030143193 Compositions and methods for modifying toxic effects of proteinaceous compounds |
| 07/31/2003 | US20030143192 Chemokine beta-7 |
| 07/31/2003 | US20030143190 For modulating the immune system; therapy of cancer |
| 07/31/2003 | US20030143183 Combined use of a GLP-1 compound and another drug for treating dyslipidemia |
| 07/31/2003 | US20030143157 Method of treating tumors |
| 07/31/2003 | CA2840490A1 Polyalkylene glycol with moiety for conjugating biologically active compounds |
| 07/31/2003 | CA2753899A1 Polyalkylene glycol with moiety for conjugating biologically active compounds |
| 07/31/2003 | CA2511257A1 Stimulation of bone growth and cartilage formation with thrombin peptide derivatives |
| 07/31/2003 | CA2511223A1 Thrombin derived peptides for promoting cardiac tissue repair |
| 07/31/2003 | CA2510751A1 Multimers of receptor-binding ligands |
| 07/31/2003 | CA2476984A1 Lactoferrin as an agent for enhancing action of an opioid |
| 07/31/2003 | CA2476773A1 Monoclonal antibodies against extracellular loops of c5ar |
| 07/31/2003 | CA2474623A1 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof |
| 07/31/2003 | CA2474292A1 Sustained release pharmaceutical composition |
| 07/31/2003 | CA2474269A1 Nutraceuticals for the treatment, protection and restoration of connective tissues |
| 07/31/2003 | CA2474056A1 Combination therapy for treatment of hiv infection |
| 07/31/2003 | CA2473944A1 Methods and compositions for rna interference |
| 07/31/2003 | CA2473927A1 Methods and compositions for treating polycystic ovary syndrome |
| 07/31/2003 | CA2473906A1 Cooperative oligonucleotides |
| 07/31/2003 | CA2473829A1 Use of tgf-.beta. antagonists to treat or to prevent chronic transplant rejection |
| 07/31/2003 | CA2473781A1 Glycoisoforms of adiponectin and uses thereof |
| 07/31/2003 | CA2473746A1 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 07/31/2003 | CA2473740A1 Methods of treating conditions associated with an edg receptor |
| 07/31/2003 | CA2473254A1 Combination therapy for the treatment of bacterial infections |
| 07/31/2003 | CA2473032A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 07/31/2003 | CA2472775A1 Synthetic peptides and uses thereof for the prevention and therapy of cancer invasion and metastasis |
| 07/31/2003 | CA2472729A1 Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression |
| 07/31/2003 | CA2472682A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | CA2472588A1 Oral administration of interferon-tau |
| 07/31/2003 | CA2472270A1 Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease |
| 07/31/2003 | CA2472241A1 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
| 07/31/2003 | CA2472186A1 Combination il-2/anti-her2 antibody therapy for cancers characterized by overexpression of the her2 receptor protein |
| 07/31/2003 | CA2471967A1 Wt1 antisense oligos for the inhibition of breast cancer |
| 07/31/2003 | CA2469685A1 Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| 07/31/2003 | CA2454358A1 Multimeric proteins and methods of making and using same |
| 07/30/2003 | EP1331271A1 The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits |
| 07/30/2003 | EP1331269A1 Novel protein, process for producing the same and use thereof |
| 07/30/2003 | EP1331268A1 Novel proteins, genes encoding them and method of using the same |
| 07/30/2003 | EP1331267A2 Oligonucleotides specific for hepatitis C virus |
| 07/30/2003 | EP1331265A2 density enhanced protein tyrosine phosphatases |
| 07/30/2003 | EP1331227A1 62113, A human acyl-CoA dehydrogenase family member and uses therefor |
| 07/30/2003 | EP1331008A1 Process for the preparation of amylase inhibitor |
| 07/30/2003 | EP1331004A2 Aminotetralin Derivative for the Therapy of Cardiovascular Diseases |
| 07/30/2003 | EP1331002A2 Oil-free pharmaceutical compositions containing cyclosporin A |
| 07/30/2003 | EP1330548A2 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries |
| 07/30/2003 | EP1330544A2 Rna aptamers and methods for identifying the same |
| 07/30/2003 | EP1330543A2 Nucleic acid sequences differentially expressed in cancer tissue |
| 07/30/2003 | EP1330538A2 Cd36 as a heat shock protein receptor and uses thereof |
| 07/30/2003 | EP1330528A2 Regulation of human serine-threonine protein kinase |
| 07/30/2003 | EP1330521A2 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 07/30/2003 | EP1330520A2 Therapeutic oligonucleotides of reduced toxicity |
| 07/30/2003 | EP1330519A2 Antisense iap nucleic acids and uses thereof |
| 07/30/2003 | EP1330515A1 Methods of agonizing and antagonizing fabk |
| 07/30/2003 | EP1330473A2 Streptococcal genes |
| 07/30/2003 | EP1330470A1 Glutathione conjugates with distamycin derivatives having antitumor activity |
| 07/30/2003 | EP1330469A2 Glycoproteins and methods of use therefof |
| 07/30/2003 | EP1330447A2 Peptides as met-ap2 inhibitors |
| 07/30/2003 | EP1330425A2 C-nitroso compounds and use thereof |
| 07/30/2003 | EP1330293A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |